Half of those surveyed plan to raise deductibles and maximum out-of-pocket costs for workers. Read more at straitstimes.com. Read more at straitstimes.com.

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...

Lilly, Johnson & Johnson, AbbVie, Pfizer and more pharma stocks shrug even amid Trump's fresh pharma tariff threats.

Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s spotlight. Answering a caller’s query about the company, Cramer said: “Alright, listen to me. This one is one that everyone’s ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 40+ ...

Lilly Endowment Community Scholarship application is now available in Carroll County through the. The Lilly Endowment Community Scholarship Program (LECSP) will provide 147 scholarships ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...